Ocular allergies affect an approximate 40% of the population, 98% of which are due to allergic conjunctivitis. With both repurposed drugs for ocular allergies and new medicines and administrative procedures now in progress, an updated analysis of existing medicines is essential. Ultimately, a straightforward characterisation of all treatments would enable doctors to recover the quality of life of patients and reduce the disease burden.Different therapies for ocular allergies have been established over the years. While several older formulations have been licenced in the eye for their direct effect on the eye pruritus, others have not received a redness certification, but newer drugs do apply to the market. This section explores existing therapies, including older drugs, recurring medicines, and new administration approaches.
There are currently a range of reformulated antihistamines, the latest ophthalmic choice being cetrizine. While antihistamines are still the gold standard for treating allergic conjunctivitis, the emergence of new medications and opioid addiction is still an exciting period. The legalisation of cetirizine as an ophthalmic solution and the development of an antihistamine lens have opened the door to comfortable and longer-life therapies.
Nonetheless, study is under way into immunotherapy, testosterone, flavonoids, cannabis and pharmaceuticals.While the secret to therapy is double-activity inhibitors, new medications and medicinal supply networks are providing other innovative ways of providing adequate relief with minimal results.
